At the moment, every pharmaceutical and biotech company in the world is researching a reliable vaccine against the new coronavirus. It is very difficult to predict which company will eventually win the race, but there are some companies that have already gained a good lead in the development of the vaccine.
Find out more about the race to find a vaccine against the COVID-19 pandemic and read the latest business news with the Born2Invest mobile app.
Vaccine hopes from Germany
Investors who assume that the big pharmaceutical and biotech companies, which are currently in the race for a vaccine, all come from the USA and China, are being disabused by the Mainz-based biotech company BioNTech and Tübingen-based CureVac. The two companies have been working for quite some time on a vaccine that uses messenger RNA to provide human cells with information that stimulates the body to support the production of specific proteins. These in turn can fight the pathogen.
According to the BIO-Deutschland industry association, BioNTech and CureVac are far from being the only biotech specialists who are currently working hard on a solution. “Many German biotech companies are currently working hard on diagnostics, vaccines and therapies against the novel coronavirus,” said Oliver Schaft, President of the German Biotech Industry Association, in a study carried out in cooperation with the management consultants EY.
The company BioNTech is currently testing four different vaccine candidates
The Mainz-based biotech group already received the green light for the first clinical study for a vaccine against the coronavirus in mid-April. With the BNT162 program, the company is currently testing four different agents that might be potential vaccines. The first results of the clinical trials are expected between June and July.
The confidence in success can also be seen in the share price of the company, which is listed on the US technology exchange Nasdaq. In the past six months, the share price has risen by around 65 percent.
CureVac hopes to bring its drug into the clinical phase this month
The Tübingen-based biopharmaceutical company CureVac, which also focuses on research into the messenger molecule mRNA, also hopes to bring its drug into the clinical phase this month. According to an announcement by the company, the new vaccine has already “achieved positive results” in animal experiments.
Soon, private investors will also have an opportunity to bet on the success of the CureVac vaccine, as the company, which is partly owned by SAP co-founder Dietmar Hopp, plans to go public in July.
Inovio Pharmaceuticals another committed competitor in the race for a vaccine
With a current market capitalization of around $1.8 billion, the relatively small US biotechnology company Inovio Pharmaceuticals is also a committed competitor in the race for a reliable vaccine. Like CureVac, Inovio was recently able to report that the latest preclinical animal experiments with the potential corona remedy called INO-4800 have been very successful.
In view of the share price performance, it can now be assumed that many investors believe that the Inovio vaccine will also achieve good results in the clinical trials whose results will be published soon. That is because the share price has already gained well over 150 percent since the beginning of March alone.
Investors think that Novavax’s vaccine will be a hit
The shareholders of the American vaccine developer Novavax are also currently expecting the first results from the clinical studies. In the company’s first clinical trial phase, 130 volunteers from Australia were treated with the potential COVID-19 healer NVX-CoV2373.
The share price development of over 250 percent within the last three months clearly shows that many investors are currently speculating that the Novavax vaccine will be a real hit. The shares of the group from Gaitersburg in the US state of Maryland are already among the biggest pandemic winners on the stock exchange. While some of the company’s shares were still being traded for less than $4 in mid-January, the price of the shares is now already well over $40.
Moderna might start the third phase of the clinical trials in July
Moderna, a biotechnology company based in Cambridge, Massachusetts, USA, also saw its share price rally. The shares of the group, which like the German manufacturers concentrates on the development of a vaccine based on messenger RNA, doubled in the past three months.
The company has now succeeded in bringing the first volunteers into the second test phase with the potential corona vaccine mRNA-1273. In this part of the program, the preparation will be tested on a total of 600 volunteers. Provided there are no further complications, the company would even like to start the third phase of its clinical trial in July.
Investors play vaccine roulette
As none of these companies has yet managed to submit an application for approval of a developed drug, the hopes and fears of the shareholders are now, however, still alive. Shareholders with a weakness for pharmaceutical and biotech stocks should, despite the constantly very positive announcements of the individual companies, bear in mind that the search for a reliable new active substance in the pharmaceutical sector is often like looking for a needle in a haystack, as usually only one drug out of 5,000 to 10,000 potential hopefuls is actually launched on the market.
Consequently, it is quite likely that the majority of potential corona vaccines will never receive marketing authorization from the competent drug authority and that the majority of research-based companies will therefore not be able to make a profit. However, as long as there is a prevailing sense of euphoria on the stock exchange, it will still be possible to make good money with one or two stocks from the biotech sector. However, as soon as disillusionment becomes widespread, investors should immediately leave.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in finanzen.at, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Many community colleges forge ahead with major expansions
COVID-19 has impacted community colleges. It is puzzling and sad to see that some community colleges have extremely dire financial...
Apart from the rise of the Ibex35, pharma stocks fell by 2.7% in the second quarter
All listed pharmaceutical companies have advanced on the stock market, but Grifols, whose shares have fallen by more than 12%,...
Why using ESG research in COVID-19 times is important
The Corona crisis presents companies with a variety of challenges. Investors who incorporate environmental, social and corporate governance (ESG) factors...
Bitcoin course rally by 4,500%? BTC signal as before the 2017 Bullrun is back
According to Glassnode, 61.33% of the BTC offer has not moved for 1 year or more, which is a new...
The coronavirus favored the fintech sector and the digitization of Italian banks
The coronavirus crisis has affected all economic sectors. However, the fintech sector managed to thrive, thanks to the confinement measures...
Business7 days ago
How to create a video marketing strategy that gets results
Crypto7 days ago
ECTM Group launches blockchain certified sanctioning
Crowdfunding6 days ago
Two innovative SMEs raised more than €500,000 each with equity crowdfunding in June
Business6 days ago
In the year 2025 if fiat currency can survive